Synchron Raises $200M to Advance Brain-Computer Interface Launch
Synchron has secured $200 million to accelerate pivotal clinical trials and gear up for the commercial launch of its Stentrode brain-computer interface (BCI) system.
Brain-Computer Interface Technologies
BCI companies develop devices that capture and interpret brain signals to enable actions like hands-free control of digital devices. However, these devices differ significantly in design and implantation methods.
While Elon Musk’s Neuralink implants a device by removing part of the skull, Synchron’s first-generation product is implanted via a catheter procedure.
Each approach balances invasiveness with signal accuracy. Synchron’s Stentrode device contains 16 electrodes, whereas Neuralink’s N1 Implant boasts 1,024 electrodes. Despite having fewer electrodes, Stentrode enables severely paralyzed individuals to control personal devices effectively.
Funding and Future Plans
The recent Series D funding positions Synchron to maximize the advantages of its current device while addressing its limitations over time.
- Accelerate pivotal trials for Stentrode.
- Prepare for commercial launch.
- Develop a next-generation, transcatheter, high-channel whole-brain interface.
Integrating Artificial Intelligence
AI plays a key role in Synchron’s strategy. The company is building an AI team in New York City focused on training models to decode brain data and ultimately interpret thoughts in real time.
Synchron’s goal is to decode thought in real time.
By combining less invasive implantation with AI-powered signal decoding, Synchron aims to expand BCI applications for people with disabilities.
Author’s summary: Synchron’s $200M funding accelerates development of a less invasive brain-computer interface integrating AI to decode thought and improve accessibility for paralyzed individuals.